Aliases & Classifications for Genitourinary Tract Anomalies

MalaCards integrated aliases for Genitourinary Tract Anomalies:

Name: Genitourinary Tract Anomalies 57

Characteristics:

OMIM:

57
Inheritance:
x-linked


HPO:

32
genitourinary tract anomalies:
Mortality/Aging neonatal death
Inheritance x-linked inheritance


External Ids:

OMIM 57 305690
MedGen 42 C1844502

Summaries for Genitourinary Tract Anomalies

MalaCards based summary : Genitourinary Tract Anomalies is related to meier-gorlin syndrome 1 and meier-gorlin syndrome 2. An important gene associated with Genitourinary Tract Anomalies is CDC6 (Cell Division Cycle 6), and among its related pathways/superpathways are CDK-mediated phosphorylation and removal of Cdc6 and Cell Cycle, Mitotic. The drugs Menotropins and Drospirenone have been mentioned in the context of this disorder. Related phenotypes are abnormality of the genitourinary system and Increased Nanog expression

Description from OMIM: 305690

Related Diseases for Genitourinary Tract Anomalies

Diseases related to Genitourinary Tract Anomalies via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 17)
# Related Disease Score Top Affiliating Genes
1 meier-gorlin syndrome 1 30.1 CDC6 CDT1 GMNN MCM5 ORC1 ORC4
2 meier-gorlin syndrome 2 11.1
3 meier-gorlin syndrome 3 11.1
4 meier-gorlin syndrome 4 11.1
5 meier-gorlin syndrome 5 11.1
6 meier-gorlin syndrome 6 11.1
7 meier-gorlin syndrome 7 11.1
8 meier-gorlin syndrome 8 11.1
9 melanoacanthoma 9.9 GMNN MCM5
10 down syndrome 9.9
11 anus, imperforate 9.9
12 acute cystitis 9.9
13 hydrocele 9.9
14 seckel syndrome 9.7 ORC4 ORC6
15 microtia 9.6 MCM5 ORC4 ORC6
16 isolated growth hormone deficiency, type ia 9.5 CDC6 CDT1 ORC4 ORC6
17 microcephaly 9.5 CDC6 CDT1 ORC4 ORC6

Graphical network of the top 20 diseases related to Genitourinary Tract Anomalies:



Diseases related to Genitourinary Tract Anomalies

Symptoms & Phenotypes for Genitourinary Tract Anomalies

Symptoms via clinical synopsis from OMIM:

57
Misc:
neonatal death

G U:
genitourinary tract anomalies


Clinical features from OMIM:

305690

Human phenotypes related to Genitourinary Tract Anomalies:

32
# Description HPO Frequency HPO Source Accession
1 abnormality of the genitourinary system 32 HP:0000119

GenomeRNAi Phenotypes related to Genitourinary Tract Anomalies according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased Nanog expression GR00371-A-1 9.65 GMNN MCM5 ORC1
2 Increased Nanog expression GR00371-A-3 9.65 GMNN MCM5 CDC6
3 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.62 CDC6 CDT1 GMNN MCM5 ORC1
4 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.62 CDC6 CDT1 GMNN MCM5 ORC1
5 Decreased viability GR00231-A 9.46 ORC1 ORC4
6 Decreased viability GR00402-S-2 9.46 ORC1 ORC4

Drugs & Therapeutics for Genitourinary Tract Anomalies

Drugs for Genitourinary Tract Anomalies (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 320)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Menotropins Approved Phase 4 61489-71-2, 9002-68-0 5360545
2
Drospirenone Approved Phase 4,Not Applicable 67392-87-4 68873
3
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 2,Not Applicable 57-63-6 5991
4
Cyproterone Acetate Approved, Investigational Phase 4,Not Applicable 427-51-0
5
Polyestradiol phosphate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 28014-46-2
6
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-28-2 5757
7 Estradiol valerate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 979-32-8
8
Progesterone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable,Early Phase 1 57-83-0 5994
9
Ropivacaine Approved Phase 4,Not Applicable 84057-95-4 175805 71273
10
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3,Phase 2 113775-47-6 68602 5311068
11
Zinc Approved, Investigational Phase 4,Phase 2 7440-66-6
12
Sevoflurane Approved, Vet_approved Phase 4,Phase 2,Not Applicable 28523-86-6 5206
13
Propofol Approved, Investigational, Vet_approved Phase 4,Not Applicable 2078-54-8 4943
14
leucovorin Approved Phase 4,Not Applicable 58-05-9 6006 143
15
Metformin Approved Phase 4,Phase 3,Phase 2,Not Applicable 657-24-9 14219 4091
16
Bupivacaine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 2180-92-9, 38396-39-3 2474
17
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-22-0 6013
18
Testosterone enanthate Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 315-37-7 9416
19
Methyltestosterone Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 58-18-4 6010
20
Testosterone undecanoate Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 5949-44-0
21
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Not Applicable 59-30-3 6037
22 Fertility Agents Phase 4,Phase 3,Phase 2,Early Phase 1
23 Follicle Stimulating Hormone Phase 4,Phase 2,Not Applicable
24 Chorionic Gonadotropin Phase 4,Not Applicable
25 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
26 Diuretics, Potassium Sparing Phase 4,Early Phase 1,Not Applicable
27 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
28 Estradiol 17 beta-cypionate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Androgen Antagonists Phase 4,Phase 2,Not Applicable
30 Contraceptive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Androgens Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
32 Contraceptive Agents, Male Phase 4,Phase 3,Not Applicable
33 Mineralocorticoids Phase 4,Phase 2,Early Phase 1,Not Applicable
34 Contraceptives, Oral Phase 4,Phase 3,Phase 2,Not Applicable
35 Estradiol 3-benzoate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36
Cyproterone Phase 4,Not Applicable 2098-66-0 5284537
37 Contraceptives, Oral, Combined Phase 4,Phase 3,Phase 2,Not Applicable
38 Antioxidants Phase 4,Phase 2,Not Applicable
39 Cyproterone acetate, ethinyl estradiol drug combination Phase 4
40 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
41 diuretics Phase 4,Early Phase 1,Not Applicable
42 Drospirenone and ethinyl estradiol combination Phase 4,Not Applicable
43 Estrogens Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Natriuretic Agents Phase 4,Early Phase 1,Not Applicable
45 Hemostatics Phase 4,Not Applicable
46 Mineralocorticoid Receptor Antagonists Phase 4,Early Phase 1,Not Applicable
47 Protective Agents Phase 4,Phase 3,Phase 2,Not Applicable
48 Adrenergic Agonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
49 Adrenergic alpha-Agonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
50 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 358)
# Name Status NCT ID Phase Drugs
1 Human Menopausal Gonadotropin Combining With Human Chorionic Gonadotropin Treat Congenital Hypogonadotropic Hypogonadism Unknown status NCT02880280 Phase 4 Human Menopausal Gonadotropin;Human Chorionic Gonadotropin
2 Hemocoagulation and Lipoperoxidation in Women Using Combined Oral Contraceptives, Correction by Antioxidants Unknown status NCT02027337 Phase 4 20 mcg ethinylestradiol /3 mg drospirenone;20 mcg ethinylestradiol/3 mg drospirenone and Selmevit;30 mcg ethinylestradiol/3 mg drospirenone;30 mcg ethinylestradiol/3 mg drospirenone and Selmevit;35 mcg ethinylestradiol/2 mg cyproterone;35 mcg ethinylestradiol/2 mg cyproterone and Selmevit
3 Ethinyl Estradiol and Cyproterone Acetate in Irregular Menstruation Unknown status NCT01103518 Phase 4 Ethinyl Estradiol + Cyproterone acetate
4 Pudendal Block Versus Caudal Block for Hypospadias Completed NCT02390388 Phase 4
5 Effects of Dexmedetomidine as Adjunct to Pudendal Block for Pediatric Penile Surgery Completed NCT02848157 Phase 4 Dexmedetomidine;plain ropivacaine;Ropivacaine
6 Growth Response in Girls With Turner Syndrome Completed NCT01734486 Phase 4 somatropin;somatropin
7 Safety of Somatropin and Induction of Puberty With 17-beta-oestradiol in Girls With Turner Syndrome Completed NCT01518062 Phase 4 somatropin;somatropin;somatropin;oestrogen
8 Evaluation of the Ease of Use, Preference, and Safety of EutropinPen Inj. Completed NCT03015909 Phase 4 Somatropin
9 Growth Hormone Treatment for the Prevention of Short Stature in Young Girls With Turner Syndrome Before the Age of 4 Years Completed NCT01066052 Phase 4 r-hGH
10 Sequential Therapy for Hypogonadotropic Hypogonadism Completed NCT01403532 Phase 4 Traditional intervention for HH using HCG and FSH;Sequential intervention for HH using HCG and FSH;Sequential intervention for HH using HCG and FSH plus zinc
11 The Effect of Induction Technique on Postoperative Pain and Agitation Completed NCT02110745 Phase 4 Sevofluorane;Propofol
12 First Year Growth Response Associated Genetic Markers Validation Phase IV Open-label Study in Growth Hormone Deficient and Turner Syndrome Pre-pubertal Children: the PREDICT Pharmacogenetics Validation Study Completed NCT01419249 Phase 4
13 Long-Term Growth and Skeletal Effects of Early Growth Hormone Treatment in Turner Syndrome Completed NCT00266656 Phase 4 Humatrope
14 Low Dose OC Therapy in Women With Polycystic Ovary Syndrome (PCOS): Impact of BMI on Hyperandrogenism Completed NCT01360996 Phase 4 3 mg DRSP/20 μg EE
15 Defining the Optimal Hormonal Replacement Therapy in Turner Syndrome Completed NCT00134745 Phase 4 estradiol
16 Norditropin NordiFlex® Device Compared to the Device Previously Used by Patients or Parents Completed NCT01245374 Phase 4
17 Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism Completed NCT00837616 Phase 4 17 B estradiol orally;17 B estradiol
18 Effects of Metformin vs Oral Contraceptives on CV Risk Markers in PCOS Completed NCT00428311 Phase 4 Metformin;Ethynyl-estradiol plus cyproterone acetate
19 Predictive Markers in Growth Hormone Deficiency (GHD) and Turner Syndrome (TS) Children Treated With SAIZEN® Completed NCT00256126 Phase 4 Saizen;Saizen
20 Effect of Intravenous Paracetamol in Combination With Caudal Ropivacaine on Quality of Postoperative Recovery in Paediatric Patients Undergoing Hypospadias Repair Recruiting NCT03781505 Phase 4 Paracetamol +caudal ropivacaine
21 Does Caudal Block Increase the Incidence of Urethrocutaneous Fistula Formation Following Hypospadias Repair in Infants? Recruiting NCT02861950 Phase 4 Caudal block with ropivacaine;penile nerve block with bupivacaine
22 Congenital Adrenal Hyperplasia Once Daily Hydrocortisone Treatment Recruiting NCT03760835 Phase 4 Conventional Glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone);Dual release hydrocortisone (plenadren)
23 TESTO: Testosterone Effects on Short-Term Outcomes in Infants With XXY Recruiting NCT03325647 Phase 4 Testosterone Cypionate 200 Milligram/Milliliter Injectable Solution;Placebo injectable saline
24 Ovarian Response to Recombinant Follicle Stimulating Hormone in Women With PCOS Recruiting NCT03252223 Phase 4 Recombinant Follicle Stimulating Hormone
25 Body Composition in Infants With Klinefelter Syndrome and Effects of Testosterone Treatment Active, not recruiting NCT02408445 Phase 4 testosterone cypionate 200mg/ml
26 Efficacy and Safety of Long Term Use of hCG or hCG Plus hMG in Males With Isolated Hypogonadotropic Hypogonadism (IHH) Not yet recruiting NCT03687606 Phase 4 Human Chorionic Gonadotropin;human menopausal gonadotropin
27 COrticosteroid in Congenital Adrenal Hyperplasia Unknown status NCT02552251 Phase 2, Phase 3
28 Effectiveness of Caudal Epidural Block on Intraoperative Blood Loss During Hypospadias Repair Completed NCT02752308 Phase 2, Phase 3 Bupivacaine;Dilute epinephrine injection;Fentanyl;dextrose plus sodium chloride.;neostigmine and atropine
29 Dexmedetomidine Infusion in Hypospadias Surgery Completed NCT00926705 Phase 3 Dexmedetomidine and Fentanyl;Fentanyl
30 Local Oestrogen Versus Placebo as Preoperative Treatment in Patients With Severe Hypospadias: Effects on Post-operative Complications Completed NCT01370798 Phase 3 promestriene;Placebo
31 Comparison of Chronocort® With Standard Glucocorticoid Therapy in Patients With Congenital Adrenal Hyperplasia Completed NCT02716818 Phase 3 Chronocort®;standard glucocorticoid therapy
32 An Open-Label, Multi-centre, Phase III Study of Local Tolerability of ZOMACTON 10MG Completed NCT00250250 Phase 3 ZOMACTON
33 A Clinical Study to Assess the Efficacy and Safety of DA-3002 Completed NCT01813630 Phase 3 DA-3002;Genotropin®
34 Induction of Puberty With 17-beta Estradiol in Girls With Turner Syndrome Completed NCT01710696 Phase 3 17-beta estradiol;17-beta estradiol
35 Use of Somatropin in Turner Syndrome Completed NCT01518036 Phase 3 somatropin;somatropin
36 Effect of a Commonly Used Antibiotic, Doxycycline, in Women With Polycystic Ovarian Syndrome Completed NCT01788215 Phase 3 doxycycline
37 The Effect of Growth Hormone in Very Young Girls With Turner Syndrome Completed NCT00406926 Phase 3 Somatropin
38 Evaluating Acceptance of New Liquid Somatropin Formulation in Children With Growth Hormone Deficiency Completed NCT01563926 Phase 3 somatropin
39 Study to Define Optimal IGF-1 Monitoring in Children Treated With NutropinAq Completed NCT00234533 Phase 3 Somatropin (rDNA origin)
40 Somatropin Treatment to Final Height in Turner Syndrome Completed NCT00191113 Phase 3 Somatropin;Ethinyl estradiol;Medroxyprogesterone acetate
41 Androgen for Leydig Cell Proliferation Completed NCT01206270 Phase 2, Phase 3 Testosterone undecanoate;Castor Oil
42 The Effect of Androgen and Growth Hormone on Height and Learning in Girls With Turner Syndrome Completed NCT00029159 Phase 3 estrogen;androgen
43 The Effect of Metformin Added to Clomiphene Citrate on Pregnancy Rates in Hyperandrogenic, Chronic Oligoovulatory or Anovulatory Women Completed NCT00413179 Phase 3 Metformin;Clomiphene citrate;Placebo
44 Estrogen Treatment (Oral vs. Patches) in Turner Syndrome Completed NCT00140998 Phase 3 17 beta estradiol
45 A Study of the Efficacy, Safety and Tolerability of Chronocort in Treating CAH Recruiting NCT03062280 Phase 3 Hydrocortisone
46 Uterus Transplantation From Live Donors and From Deceased Donors - Clinical Study Recruiting NCT03277430 Phase 3 Tacrolimus
47 Primary Ovarian Insufficiency: Phenotype and Optimal Treatment Recruiting NCT03568708 Phase 3 Transdermal Estrogen
48 Hormone Replacement for Premature Ovarian Insufficiency Recruiting NCT02922348 Phase 3 Hormone Replacement Therapy;Combined Oral Contraceptives
49 A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome - CARDINAL Active, not recruiting NCT03019185 Phase 2, Phase 3 Placebo Oral Capsule;Bardoxolone Methyl
50 Efficacy and Safety Study to Delay Renal Failure in Children With Alport Syndrome Active, not recruiting NCT01485978 Phase 3 Ramipril;placebo to ramipril;Ramipril

Search NIH Clinical Center for Genitourinary Tract Anomalies

Genetic Tests for Genitourinary Tract Anomalies

Anatomical Context for Genitourinary Tract Anomalies

Publications for Genitourinary Tract Anomalies

Articles related to Genitourinary Tract Anomalies:

(show all 12)
# Title Authors Year
1
Associated genitourinary tract anomalies in anorectal malformations: a thirteen year review. ( 12117016 )
2002
2
Lower genitourinary tract anomalies in a male with Down syndrome. ( 7567270 )
1995
3
Surgical implications of genitourinary tract anomalies in patients with imperforate anus. ( 8201665 )
1994
4
Fetal genitourinary tract anomalies: evaluation, operative correction, and follow-up. ( 2296425 )
1990
5
Genitourinary tract anomalies in Thai children with urinary tract infection. ( 2732647 )
1989
6
Genitourinary tract anomalies: neonatal medical problems. ( 3455137 )
1986
7
Genitourinary tract anomalies: neonatal surgical problems. ( 3455138 )
1986
8
Ultrasound diagnosis of fetal genitourinary tract anomalies. ( 7179604 )
1982
9
Genitourinary tract anomalies in lobster claw syndrome. ( 1255902 )
1976
10
Ultrasound efficacy in evaluation of lower genitourinary tract anomalies. ( 803989 )
1975
11
Legg-Perthes' disease and genitourinary-tract anomalies. ( 4104804 )
1971
12
Laurence-Moon-Biedl syndrome, associated with multiple genitourinary tract anomalies. ( 5765158 )
1969

Variations for Genitourinary Tract Anomalies

Expression for Genitourinary Tract Anomalies

Search GEO for disease gene expression data for Genitourinary Tract Anomalies.

Pathways for Genitourinary Tract Anomalies

Pathways related to Genitourinary Tract Anomalies according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.8 CDC6 CDT1 GMNN MCM5 ORC1 ORC4
2
Show member pathways
13.03 CDC6 CDT1 GMNN MCM5 ORC1 ORC4
3
Show member pathways
12.37 CDC6 MCM5 ORC1 ORC4 ORC6
4 12.24 CDC6 CDT1 GMNN ORC1 ORC6
5
Show member pathways
12.15 CDC6 CDT1 MCM5 ORC1 ORC4 ORC6
6 12.01 CDC6 MCM5 ORC1 ORC4 ORC6
7
Show member pathways
11.87 CDC6 CDT1 GMNN MCM5 ORC1 ORC4
8 11.44 CDT1 ORC1
9 11.34 CDC6 ORC1
10 11.34 CDC6 GMNN ORC1
11 10.73 CDC6 CDT1 MCM5 ORC1 ORC4 ORC6

GO Terms for Genitourinary Tract Anomalies

Cellular components related to Genitourinary Tract Anomalies according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.87 CDC6 CDT1 GMNN MCM5 ORC1 ORC4
2 cytosol GO:0005829 9.85 CDC6 CDT1 GMNN MCM5 ORC1 ORC4
3 nucleoplasm GO:0005654 9.7 CDC6 CDT1 GMNN MCM5 ORC1 ORC4
4 nuclear chromosome, telomeric region GO:0000784 9.43 MCM5 ORC1 ORC4
5 nuclear origin of replication recognition complex GO:0005664 9.13 ORC1 ORC4 ORC6
6 origin recognition complex GO:0000808 8.8 ORC1 ORC4 ORC6

Biological processes related to Genitourinary Tract Anomalies according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 cell cycle GO:0007049 9.8 CDC6 CDT1 GMNN MCM5
2 cell division GO:0051301 9.69 CDC6 CDT1 MCM5
3 mitotic cell cycle GO:0000278 9.63 CDC6 CDT1 ORC1
4 DNA replication GO:0006260 9.63 CDC6 CDT1 MCM5 ORC1 ORC4 ORC6
5 negative regulation of DNA replication GO:0008156 9.48 CDC6 GMNN
6 positive regulation of chromatin binding GO:0035563 9.43 CDT1 GMNN
7 regulation of transcription involved in G1/S transition of mitotic cell cycle GO:0000083 9.43 CDC6 CDT1 ORC1
8 mitotic DNA replication checkpoint GO:0033314 9.4 CDC6 ORC1
9 DNA replication checkpoint GO:0000076 9.37 CDC6 CDT1
10 DNA replication initiation GO:0006270 9.35 CDC6 MCM5 ORC1 ORC4 ORC6
11 DNA replication preinitiation complex assembly GO:0071163 9.32 CDT1 GMNN
12 G1/S transition of mitotic cell cycle GO:0000082 9.17 CDC6 CDT1 GMNN MCM5 ORC1 ORC4

Molecular functions related to Genitourinary Tract Anomalies according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ATP binding GO:0005524 9.62 CDC6 MCM5 ORC1 ORC4
2 DNA binding GO:0003677 9.55 CDT1 MCM5 ORC1 ORC4 ORC6
3 chromatin binding GO:0003682 9.43 CDT1 GMNN ORC1
4 nucleotide binding GO:0000166 9.26 CDC6 MCM5 ORC1 ORC4
5 DNA replication origin binding GO:0003688 9.02 CDC6 MCM5 ORC1 ORC4 ORC6

Sources for Genitourinary Tract Anomalies

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....